Clinical Trial Search

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Hepatitis C Virus (HCV) Genotype (GT) 1,2,4,5 and 6-infected Participants…

Primary: Intraoperative Blood Loss — 510; 500 ml — p=0.315

Primary: Number of Infants and Children With Newly Diagnosed Chronic Medical Conditions (After 28 Days Post Estimated Date of Delivery) — 0; 1; 3 Participants

Primary: Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days — -1.02; -4.14 Days — p=<0.0001

Primary: Hemodynamics as Characterized by Vasoactive Inotrope Score (VIS) — 11; 11.3 units

Primary: Change in Truncal Fat Percentage (Week 34) — 0.49; -2.39; -1.17 Percentage of truncal fat — p==0.0090

Primary: Seroprotection Rate (SPR) Defined as Percentage of Adults ≥ 18 Years Old Achieving Anti-HBs Levels of ≥10 mIU/mL in Serum at Study Day 196 — 76.49; 91.36 percentage of…

Primary: Number of Participants With Opioid Abstinence at 8 Weeks — 0; 1 Participants — p=0.44

Primary: Change in HbA1c — -1.71; -1.20; -1.16 Percentage points of HbA1c — p=<0.0001

Primary: Change From Baseline to Week 12/Early Termination in the Cohen-Mansfield Agitation Inventory (CMAI) Total Score — -18.9; -16.5 units on a scale — p==0.1454

Primary: Composite Primary Endpoint — 81; 38; 170; 83 Participants — p== 0.0001

Primary: Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months — 28; 22 Participants

Primary: Preeclampsia — 169; 156 Participants — p=0.37

Primary: Event-free Survival (EFS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations — 45.64; 46.95 percentage of patients

Primary: Gastroparesis Symptom Assessment (GSA), a Patient Reported Outcome Measure — -0.751; -0.657 score on a scale — p=0.597